₹ 2,363.39 Cr
2.0%
S&P BSE Healthcare TRI
INF740KA1LD8
100.0
100.0
500
Jay Kothari, Chirag Dagli
Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
---|---|---|---|
DSP Healthcare Fund - Regular Plan - Growth | 45.58 | 15.61 | 27.95 |
S&P BSE Healthcare TRI | 50.08 | 13.58 | 22.23 |
Equity
Debt
Others
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Company | Holdings (%) |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.59 |
Cipla Ltd. | 8.49 |
Ipca Laboratories Ltd. | 7.82 |
Suven Pharmaceuticals Ltd. | 7.56 |
Lupin Ltd. | 7.32 |
Alembic Pharmaceuticals Ltd. | 5.56 |
Globus Medical Inc | 5.51 |
Apollo Hospitals Enterprise Ltd. | 4.6 |
Zydus Lifesciences Ltd. | 4.39 |
Concord Biotech Ltd. | 3.87 |
Sector | Holdings (%) |
---|---|
Healthcare | 96.26 |
Insurance | 1.61 |
Others | 1.25 |
Financial | 0.88 |
Scheme Name | 5Y (%) |
---|---|
DSP Healthcare Reg Gr | 27.95 |
ICICI Pru Pharma Healthcare and Diagnostics PHD Fund Cum | 27.6 |
ABSL Pharma and Healthcare Reg Gr | 0.0 |
Tata India Pharma & Healthcare Reg Gr | 25.17 |
UTI Healthcare Reg Gr | 24.81 |
Nippon India Pharma Fund Gr Gr | 26.37 |
Mirae Asset Healthcare Reg Gr | 27.12 |
LIC MF Healthcare Fund Reg Gr | 20.85 |
SBI HEALTHCARE Opportunities Reg Gr | 26.98 |
ITI Pharma and Healthcare Fund Reg Gr | 0.0 |